Skip to main content

Table 2 Patients’ Characteristics in 75 patients

From: Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Parameter Total
(%)(N = 75)
Typical response (%)(N = 24) Typical progression (%)(N = 15) iUPD (%)(N = 9) Stable Disease (%)(N = 25) Pseudoprogression (%)(N = 2) P Value
Gender        0.06
 Male 48 (64) 12 (50) 10 (66) 9 (100) 15 (60) 2 (100)  
 Female 27 (36) 12 (50) 5 (33) 0 10 (40) 0  
Mean age ± SD, y 48.8 ± 14.15 46.2 ± 15.6 48.3 ± 16.27 56.3 ± 8.18 48.84 ± 12.75 49 ± 19.79 0.51
Clinical T stage (cT)        0.28
 T1–3 36 (48) 13 (54) 3 (20) 5 (55) 14 (56) 1 (50)  
 T4 24 (32) 7 (29) 8 (53) 4 (44) 4 (16) 1 (50)  
 Not investigated 15 (20) 4 (16) 4 (26) 0 7 (28) 0  
Clinical N stage (cN)        0.98
 0 11 (14) 4 (16) 2 (13) 3 (33) 2 (8) 0  
 N1 21 (28) 8 (33) 5 (33) 2 (22) 4 (16) 2 (100)  
 N2 27 (36) 8 (33) 4 (26) 4 (44) 11 (44) 0  
 Not investigated 16 (21) 4 (16) 4 (26) 0 8 (32) 0  
Clinical M stage (cM)        0.94
 0 23 (30) 7 (29) 2 (13) 4 (44) 9 (36) 1 (50)  
 1 38 (50) 13 (54) 9 (60) 5 (55) 10 (40) 1 (50)  
 Not investigated 14 (18) 4 (16) 4 (26) 0 6 (24) 0  
Mean treatment course ± SD        0.007
8.6 ± 7.3 12.2 ± 8.9 8.7 ± 4.5 3.0 ± 1.2 6.8 ± 6.6 11.5 ± 9.2  
Mismatch Repair Status        0.04
 Mismatch Repair-Proficient (pMMR) 41 (54) 12 (50) 7 (46) 9 (100) 12 (48) 1 (50)  
 Mismatch Repair-Deficient (dMMR) 22 (29) 9 (37) 2 (13) 0 10 (40) 1 (50)  
 Not investigated 12 (16) 3 (12) 6 (40) 0 3 (12) 0  
Histologic types        0.72
 Adenocarcinoma 58 (77) 20 (83) 9 (60) 9 (100) 18 (72) 2 (100)  
 Mucinous adenocarcinoma 8 (10) 2 (8) 2 (13) 0 4 (16) 0  
 Signet ring cell carcinoma 1 (1) 0 1 (6) 0 0 0  
 Other 8 (10) 2 (8) 3 (20) 0 3 (12) 0  
KRAS status        0.54
 Wild-type 21 (28) 6 (25) 3 (20) 4 (44) 7 (28) 1 (50)  
 Mutated 16 (21) 6 (25) 2 (13) 1 (11) 7 (28) 0  
 Not investigated 38 (50) 12 (50) 10 (66) 4 (44) 11 (44) 1 (50)